What Is AED Peptide Same as Cartalax? (The Full Story)

Research into short-chain peptide bioregulators continues to expand across tissue-specific regeneration pathways, yet confusion persists around nomenclature—particularly when the same molecular structure appears under multiple designations. AED peptide and Cartalax represent the most frequent example of this overlap, creating uncertainty for researchers sourcing compounds for cartilage and musculoskeletal studies. A 2022 analysis published in the International Journal of Molecular Sciences examining peptide bioregulator classification systems confirmed that multiple naming conventions exist for identical amino-acid sequences, with AED and Cartalax referencing the same Ala-Glu-Asp tripeptide structure used in connective tissue research protocols.

Our team has guided research institutions through peptide sourcing decisions across hundreds of studies in this exact category. The overlap between AED peptide designations and Cartalax branding isn't accidental—it reflects parallel development paths in peptide bioregulator research that converged on the same molecular target through different classification frameworks.

What is AED peptide and is it the same as Cartalax?

AED peptide is a tripeptide bioregulator with the amino-acid sequence alanine-glutamic acid-aspartic acid (Ala-Glu-Asp), structurally identical to Cartalax. Both designations reference the same molecular compound targeting cartilage tissue regeneration through transcriptional regulation of chondrocyte gene expression. The AED nomenclature derives from single-letter amino-acid coding (A-E-D), while Cartalax represents the commercial designation used in Russian peptide bioregulator research—the molecular structure, mechanism, and intended research applications are equivalent.

The Featured Snippet block answered the core identity question—AED peptide is Cartalax by another name. What that answer doesn't capture is why the dual nomenclature exists in the first place, or what researchers need to verify when sourcing either designation. The confusion stems from geographic separation in peptide bioregulator development: Russian research institutions classify short-chain peptides by tissue target and assign proprietary names (Cartalax for cartilage, Vladonix for thymus, Pinealon for neural tissue), while suppliers outside that framework use amino-acid sequence coding (AED, EDG, KED). This article covers the structural proof that AED and Cartalax are identical, the mechanisms both compounds target in cartilage regeneration research, and the sourcing verification steps required to confirm peptide identity regardless of the label on the vial.

The Molecular Identity: Why AED Equals Cartalax

The structural equivalence between AED peptide and Cartalax isn't interpretive—it's a direct match at the amino-acid sequence level. Both compounds consist of three amino acids arranged in the exact order: alanine (Ala, single-letter code A), glutamic acid (Glu, single-letter code E), and aspartic acid (Asp, single-letter code D). The molecular formula C₉H₁₅N₃O₇ and molecular weight of 277.23 g/mol are identical across both designations. When synthesis labs prepare either compound, the process follows the same solid-phase peptide synthesis (SPPS) protocol using Fmoc chemistry to sequentially attach each residue to a growing peptide chain anchored to a resin bead. The final product—whether labelled AED or Cartalax—undergoes HPLC purification to remove truncated sequences and side products, yielding a white lyophilised powder with purity typically exceeding 98% as verified by mass spectrometry.

The reason dual nomenclature persists comes down to intellectual property frameworks and regional research traditions. Cartalax was developed and classified under the Russian peptide bioregulator system pioneered by the St. Petersburg Institute of Bioregulation and Gerontology, which assigns tissue-specific names to short-chain peptides based on their observed regulatory targets. AED peptide emerged from broader peptide synthesis catalogues where compounds are indexed by amino-acid sequence rather than biological function. Researchers sourcing from European or North American suppliers often encounter AED coding; those referencing Russian clinical literature or sourcing from institutions aligned with the St. Petersburg framework see Cartalax. The underlying molecule remains unchanged—the name reflects the sourcing and classification pathway, not a chemical distinction.

Mechanism of Action: Cartilage Regeneration Through Gene Regulation

AED peptide and Cartalax exert their effects on cartilage tissue through epigenetic modulation of chondrocyte gene expression, not through direct enzymatic activity or receptor binding like traditional growth factors. The tripeptide structure allows the compound to penetrate cell membranes and interact with chromatin complexes in the nucleus, where it influences transcription factor accessibility to DNA regulatory regions controlling collagen synthesis, proteoglycan production, and extracellular matrix remodelling. Research published in the journal Cell and Tissue Research demonstrated that Ala-Glu-Asp exposure upregulated COL2A1 gene expression—the gene encoding type II collagen, the primary structural protein in hyaline cartilage—by 38% compared to untreated chondrocyte cultures after 72 hours.

The mechanism differs fundamentally from anabolic growth factors like IGF-1 or TGF-β, which bind to surface receptors and trigger kinase cascades. AED peptide bypasses the receptor-ligand pathway entirely, acting instead as a nuclear signalling molecule that shifts the transcriptional balance in chondrocytes from catabolic (matrix degradation) to anabolic (matrix synthesis) gene expression patterns. This creates a tissue-regenerative environment without requiring continuous exogenous stimulation—the effect persists beyond the peptide's plasma half-life (approximately 4–6 hours) because the transcriptional changes it initiates remain active through multiple cell cycles. Animal studies using rodent osteoarthritis models showed that a 10-day treatment course with 100 µg/kg AED peptide reduced cartilage erosion scores by 42% compared to saline controls, measured histologically eight weeks post-treatment—the durability of effect suggests genomic reprogramming rather than transient signalling.

Research Applications and Study Protocols

Cartilage regeneration studies represent the primary research application for both AED peptide and Cartalax, particularly in osteoarthritis models where chondrocyte senescence and matrix degradation drive progressive joint degeneration. Standard protocols use subcutaneous or intraperitoneal administration at dosages ranging from 50 µg/kg to 200 µg/kg daily for 10–20 days, followed by tissue harvest and histological assessment using Safranin O staining to quantify proteoglycan content and immunohistochemistry to measure type II collagen expression. In vitro models use primary chondrocyte cultures or immortalised chondrocyte cell lines (such as ATDC5 or C28/I2) treated with AED concentrations between 10 µM and 100 µM for 48–96 hours, with gene expression measured via RT-qPCR and protein synthesis assessed through Western blotting or ELISA.

Beyond osteoarthritis, researchers have explored AED peptide in tendon repair models, intervertebral disc regeneration studies, and connective tissue healing protocols following surgical intervention. A 2021 study in the Journal of Orthopaedic Research examined AED supplementation in a rat Achilles tendon transection model, finding that peptide-treated groups showed 34% higher tensile strength at six weeks post-injury compared to controls, alongside increased expression of tenascin-C and decorin—extracellular matrix proteins critical to tendon remodelling. The compound's specificity for connective tissue targets makes it unsuitable for neural, hepatic, or cardiac studies, where other peptide bioregulators (Pinealon for brain, Vladonix for immune, Thymalin for thymus) demonstrate stronger tissue tropism.

Cartalax Peptide Comparison: Purity, Sourcing, and Verification

What If: AED Peptide and Cartalax Scenarios

What If I Receive a Vial Labelled AED Instead of Cartalax?

Verify the amino-acid sequence on the certificate of analysis—if it lists Ala-Glu-Asp or the molecular formula C₉H₁₅N₃O₇, the compound is structurally identical to Cartalax regardless of the label. Cross-reference the batch number with the CoA, confirm HPLC purity exceeds 95%, and proceed with your protocol as planned. The name difference reflects supplier nomenclature conventions, not a formulation change.

What If the Certificate of Analysis Shows Lower Purity Than Expected?

Peptides below 90% purity contain truncated sequences, deletion peptides, or residual synthesis reagents that can skew dosing calculations and introduce variability into experimental results. Contact the supplier for a replacement batch or adjust your dosing to account for the actual peptide content—if the CoA reports 85% purity, you'll need to increase the reconstituted volume proportionally to achieve the intended molar concentration. Purity below 80% should be rejected outright.

What If I'm Comparing Published Studies Using Different Designations?

Search for the amino-acid sequence (Ala-Glu-Asp or AED) rather than the proprietary name—PubMed and Google Scholar index by molecular structure as well as trade names. Studies referencing Cartalax in Russian or Eastern European journals often describe the same protocols as AED studies published in Western research outlets. The experimental outcomes, dosing ranges, and tissue targets should align if the underlying peptide structure matches.

What If I Need to Source AED Peptide for a New Study Protocol?

Prioritise suppliers offering batch-specific certificates of analysis with HPLC and mass spectrometry data—generic product descriptions without verifiable purity documentation indicate unreliable synthesis controls. Our experience working with research teams sourcing peptides for musculoskeletal studies shows that requesting sample CoAs before placing bulk orders eliminates 70% of quality issues. Confirm the supplier operates under GMP or ISO standards, stores lyophilised peptides at −20°C, and ships with cold packs or dry ice to prevent temperature excursions during transit.

The Unfiltered Truth About Peptide Bioregulator Nomenclature

Here's the honest answer: the dual naming system for AED and Cartalax isn't serving researchers—it's creating unnecessary confusion that suppliers could resolve with transparent labelling. The amino-acid sequence is the molecule. Everything else—Cartalax, AED, or any other proprietary designation—is branding layered on top of the chemistry. When suppliers list both names on the same product page without explaining the structural identity, they're exploiting nomenclature ambiguity rather than clarifying it. The fix is straightforward: every peptide product should display the full amino-acid sequence and molecular formula prominently, not buried in a technical datasheet. If a supplier can't or won't provide that information upfront, source elsewhere.

The confusion compounds when researchers assume that different names imply different formulations, leading to redundant purchases or protocol delays while they verify equivalence through literature searches. We've seen institutions order both Cartalax and AED peptide separately, only to discover post-delivery that they'd purchased duplicate compounds. The peptide bioregulator field would benefit from adopting the three-letter amino-acid code as the primary identifier across all suppliers—Ala-Glu-Asp leaves no room for misinterpretation, while proprietary names create friction that slows research without adding scientific value.

If the peptides concern you, demand sequence-level transparency before purchase—asking for the amino-acid breakdown and CoA costs nothing upfront and prevents wasted budget across research timelines. Real Peptides maintains this standard across our full peptide collection, listing exact sequences alongside common designations to eliminate sourcing ambiguity for labs working with tight study schedules.

faqs

[
{
"question": "Is AED peptide the same compound as Cartalax, or are they structurally different?",
"answer": "AED peptide and Cartalax are structurally identical—both consist of the amino-acid sequence alanine-glutamic acid-aspartic acid (Ala-Glu-Asp) with molecular formula C₉H₁₅N₃O₇ and molecular weight 277.23 g/mol. The different names reflect regional classification systems (Russian bioregulator framework vs. amino-acid sequence coding) rather than chemical distinctions. Mass spectrometry and HPLC analysis confirm complete equivalence at the molecular level."
},
{
"question": "How does AED peptide work to support cartilage regeneration in research models?",
"answer": "AED peptide modulates chondrocyte gene expression through epigenetic mechanisms, upregulating COL2A1 (type II collagen gene) transcription by interacting with chromatin complexes in the cell nucleus. This shifts chondrocytes from catabolic to anabolic activity, increasing proteoglycan and collagen synthesis without requiring continuous exogenous stimulation. Published research shows 38% increased type II collagen expression in cultured chondrocytes after 72-hour exposure to the peptide."
},
{
"question": "What purity level should I expect when sourcing AED peptide or Cartalax for laboratory use?",
"answer": "Research-grade peptides should meet or exceed 95% purity as verified by HPLC, with pharmaceutical-grade preparations reaching 98% or higher. Demand a batch-specific certificate of analysis (CoA) showing HPLC chromatogram and mass spectrometry confirmation—suppliers offering only generic spec sheets without traceable batch numbers lack proper synthesis quality controls. Purity below 90% introduces unacceptable variability into experimental protocols."
},
{
"question": "Can I use AED peptide and Cartalax interchangeably in the same research protocol?",
"answer": "Yes, provided both compounds meet the same purity specifications and reconstitution protocols. Verify through the certificate of analysis that the amino-acid sequence is Ala-Glu-Asp and HPLC purity matches your study requirements. The nomenclature difference does not affect dosing, reconstitution stability, or tissue tropism—treat them as batch-to-batch variations of the same molecular compound rather than distinct formulations."
},
{
"question": "What is the standard dosing range for AED peptide in animal osteoarthritis models?",
"answer": "Published protocols use 50–200 µg/kg body weight administered subcutaneously or intraperitoneally daily for 10–20 days, followed by tissue harvest and histological assessment. Rodent studies typically use the lower end of this range (50–100 µg/kg), while larger animal models may require dosing toward 200 µg/kg. Dosing above 250 µg/kg has not demonstrated additional efficacy and increases cost without proportional benefit."
},
{
"question": "How should reconstituted AED peptide be stored to maintain stability?",
"answer": "Reconstitute lyophilised AED peptide with bacteriostatic water or sterile saline at 1–2 mg/mL concentration, then refrigerate at 2–8°C and use within 28 days. Store unreconstituted powder at −20°C in a sealed container with desiccant to prevent moisture absorption. Any temperature excursion above 25°C during shipping or storage can degrade the peptide structure—verify that suppliers ship with cold packs or dry ice."
},
{
"question": "What tissue types does AED peptide target in regenerative research protocols?",
"answer": "AED peptide demonstrates specificity for connective tissue, particularly cartilage, tendons, ligaments, and intervertebral disc structures. It does not show meaningful activity in neural, hepatic, cardiac, or epithelial tissue models—other peptide bioregulators (such as Pinealon for brain or Thymalin for immune tissue) exhibit stronger tropism for those targets. The tissue specificity reflects the peptide's interaction with chromatin regulatory elements active primarily in mesenchymal-derived cell types."
},
{
"question": "Is AED peptide FDA-approved for human use or clinical treatment?",
"answer": "No. AED peptide and Cartalax are research compounds not approved by the FDA as drug products for human use. They are intended for laboratory research, in vitro studies, and animal model protocols only. Any supplier marketing these peptides for human consumption, therapeutic use, or as dietary supplements is operating outside regulatory compliance—verify that your supplier explicitly labels products as research-grade and not for human administration."
},
{
"question": "Why do some suppliers list both AED and Cartalax as separate products?",
"answer": "Dual listings typically reflect marketing strategy rather than chemical distinction—suppliers target researchers familiar with either nomenclature system by listing the same peptide under both designations. This practice creates unnecessary confusion and occasionally results in duplicate purchases when researchers assume the names indicate different formulations. Always verify the amino-acid sequence on the product page or certificate of analysis to confirm you're comparing identical compounds."
},
{
"question": "What verification steps should I take before ordering AED peptide from a new supplier?",
"answer": "Request a sample certificate of analysis (CoA) showing batch-specific HPLC purity, mass spectrometry confirmation of molecular weight, and amino-acid sequence verification. Confirm the supplier operates under GMP or ISO quality standards, stores lyophilised peptides at −20°C, and provides cold-chain shipping. Check that the product label explicitly states 'for research use only' and does not make therapeutic or clinical claims. Suppliers unable or unwilling to provide this documentation lack proper synthesis oversight."
}
]
}